vortioxetine – FDA Approves Brintellix to Treat Major Depressive Disorder

New Drug Approvals

Vortioxetine

ボルチオキセチン  臭化水素酸塩

1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine

Lu AA21004

VORTIOXETINE; CAS 508233-74-7;

1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine; Lu AA21004; UNII-3O2K1S3WQV; C18H22N2S;

Molecular Formula: C18H22N2S
Molecular Weight: 298.44568 g/mol

Vortioxetine Hydrobromide

C18H22N2S.HBr : 379.36
[960203-27-4] HYDROBROMIDE

Vortioxetine is an atypical antipsychotic and antidepressant indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and simulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonintransporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to…

View original post 5,318 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s